Indivior Pharmaceuticals Inc
INDVNASDAQHealthcare● Active
$37.62
+$0.17(+0.44%)
Market Cap$4.7B
P/E Ratio—
52W High$41
52W Low$13.42
Indivior Pharmaceuticals Inc (INDV) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · INDV · as of 2026-06-08
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.21B | $0.00B | ($0.13B) | ($0.04B) | $0.21B |
| Depreciation & Amort. | $0.02B | $0.03B | $0.01B | $0.02B | $0.02B |
| Stock-Based Comp. | $0.03B | $0.02B | $0.02B | $0.02B | $0.01B |
| Change in Working Capital | ($0.26B) | ($0.04B) | ($0.29B) | $0.12B | $0.17B |
| Net Cash from Operations | ($0.03B) | $0.04B | ($0.30B) | ($0.00B) | $0.35B |
| Investing Activities | |||||
| Capital Expenditure | ($0.07B) | ($0.03B) | ($0.05B) | ($0.01B) | ($0.03B) |
| Purchases of Investments | ($0.02B) | ($0.02B) | ($0.04B) | ($0.24B) | $0.00B |
| Sales of Investments | $0.00B | $0.12B | $0.13B | $0.03B | $0.00B |
| Net Cash from Investing | ($0.07B) | $0.07B | ($0.10B) | ($0.22B) | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.01B) | ($0.17B) | ($0.03B) | ($0.09B) | ($0.10B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.02B) | $0.09B | ($0.01B) | ($0.00B) | $0.01B |
| Net Cash from Financing | ($0.03B) | ($0.10B) | ($0.06B) | ($0.10B) | ($0.09B) |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.09B) | $0.01B | ($0.35B) | ($0.01B) | $0.32B |
| FCF Margin %(computed) | -7.51% | 0.59% | -32.30% | -1.00% | 40.33% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Indivior Pharmaceuticals Inc data
About Indivior Pharmaceuticals Inc (INDV) Cash Flow Statement
Indivior Pharmaceuticals Inc generated operating cash flow of ($0.03B) and free cash flow of ($0.09B) for 2025 — a FCF margin of -7.51%. Capital expenditure was ($0.07B).
Frequently asked questions
INDV · 4 questionsIndivior Pharmaceuticals Inc generated free cash flow of ($0.09B) for 2025, down 1428.6% year-over-year.
INDV free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08